InVivoMab anti-human PD-L1 (B7-H1) BE0285-R001mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-human PD-L1 (B7-H1) Monoclonal Antibody has the following reported applications: in vitro PD-L1 blockade, Functional assays, Immunohistochemistry (frozen), Flow cytometry. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-human PD-L1 (B7-H1)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0285-R001mg
ImmunogenFull length human PD-L1
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology
ReactivityHuman (Hu)
ClonalityMonoclonal
NCBI Gene AliasesB7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1
NCBI Full Gene NameCD274 molecule
ApplicationsFCM, IHC-fr, BL, FA
Hostmouse
Clone29E.2A3
IsotypeIgG2b, κ
TargetPD-L1
Conjugate/TagUnconjugated
ConcentrationLot specific,typically between 4-11 mg/ml
Quantity1 mg

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine ProductionVaccinesAugust 7, 2019Broos K, Lecocq Q, Keersmaecker B, Raes G, Corthals J, Lion E, Thielemans K, Devoogdt N, Keyaerts M, Breckpot K.

(2) Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discoveryOncoimmunologyJanuary 1, 2019Sivakumar R, Chan M, Shin JS, Nishida-Aoki N, Kenerson HL, Elemento O, Beltran H, Yeung R, Gujral TS.

(3) Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functionsJournal of virologyMarch 1, 2014Porichis F, Hart MG, Zupkosky J, Barblu L, Kwon DS, McMullen A, Brennan T, Ahmed R, Freeman GJ, Kavanagh DG, et al.

(4) Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligandsJournal of autoimmunityAugust 1, 2011Hegde S, Lockridge JL, Becker YA, Ma S, Kenney SC, Gumperz JE.

(5) Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockadePLoS pathogensFebruary 1, 2009Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, Gostick E, Price DA, Freeman GJ, Wherry EJ, et al.

(6) PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cellsCellular immunologyAugust 1, 2004Cai G, Karni A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ.

(7) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine productionJournal of immunology (Baltimore, Md. : 1950)February 1, 2003Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ.

Be the First to Write a Review!